NeuroPhage wraps a $27M round to advance its Alzheimer's drug

Cambridge, MA's NeuroPhage banked an additional $10 million in Series D cash, bringing its latest round to $27 million and filling out the biotech's war chest as it marches toward the clinic with a treatment for neurodegenerative disease. The new cash will support NPT088, a drug that targets the protein misfolding at the heart of Alzheimer's and Parkinson's diseases, unblinding the body's defenses to spur a natural response to toxic buildups. NeuroPhage plans to get its top prospect into Phase I trials by the end of this year, all the while working on next-generation therapies based on the same platform. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.